Stevanato Group, a leading global provider of drug containment, drug delivery, and diagnostic solutions, with a major facility here in Fishers, has announced its financial results for the fourth quarter and full fiscal year 2024, reporting steady growth and a positive outlook for the year ahead.

Q4 and Full-Year 2024 Financial Performance

Stevanato Group’s revenue for the fourth quarter of 2024 increased by 3% year-over-year, reaching €330.6 million. The company’s high-value solutions segment accounted for 40% of total revenue, aligning with prior expectations.

For the full fiscal year 2024, revenue rose by 2% to €1,104 million, with high-value solutions representing 38% of total revenue. Diluted EPS for the year was €0.43, while adjusted diluted EPS was €0.48. (€ stands for Euros)

Strong 2025 Outlook

Looking ahead, Stevanato Group has set ambitious financial guidance for fiscal year 2025. The company anticipates revenue to be in the range of €1,160 million to €1,190 million.

Stevanato Group remains focused on expanding its high-value solutions portfolio and enhancing operational efficiencies as it continues to serve the pharmaceutical, biotechnology, and life sciences industries. The company’s consistent financial performance and strong guidance signal confidence in sustained growth and innovation for the coming year.